Survival of pleurectomy-decortication and hyperthermic chemotherapy in mesothelioma

Basit Öğe Kaydı
dc.authorscopusid55343710200
dc.authorscopusid57194325797
dc.authorscopusid58209207600
dc.authorscopusid55343779100
dc.authorscopusid37052683100
dc.authorscopusid8429335700
dc.authorscopusid6602854011
dc.contributor.authorErgönül, Ayşe Gül
dc.contributor.authorAydın, Sercan
dc.contributor.authorKahraman Aydın, Seda
dc.contributor.authorAkçam, Tevfik İlker
dc.contributor.authorÖzdil, Ali
dc.contributor.authorTurhan, Kutsal
dc.contributor.authorÇakan, Alpaslan
dc.date.accessioned2024-08-25T18:45:11Z
dc.date.available2024-08-25T18:45:11Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: This study aims to evaluate overall survival, disease -free survival, and prognostic factors in patients undergoing pleurectomy-decortication and hyperthermic intrathoracic chemotherapy with the diagnosis of malignant pleural mesothelioma. Methods: Between January 2020 and November 2021, a total of 53 patients (27 males, 26 females; mean age: 58.1 & PLUSMN;1.3 years; range, 39 to 81 years) who underwent pleurectomy-decortication and hyperthermic intrathoracic chemotherapy with the diagnosis of malignant pleural mesothelioma were retrospectively analyzed. Data including characteristics, comorbidities, postoperative complications, recurrence and mortality status of the patients were recorded. Overall survival and disease-free survival and prognostic factors were evaluated. Results: The median disease-free survival was 11.67 months and the median overall survival was 24.60 months. The median disease-free survival was 8.80 months in men and 13.17 months in women, indicating a statistically significant difference as it showed that recurrence was detected earlier in male patients (p=0.037). The median disease-free survival and overall survival was 6.13 months and 11.70 in cases diagnosed with biphasic mesothelioma, respectively, while it was 11.67 months and 25.46 months in cases with epithelial mesothelioma, respectively. Pathological subtype was found to be an effective prognostic factor for both survival (p=0.049 and p<0.001, respectively). Conclusion: Hyperthermic intrathoracic chemotherapy following cytoreductive surgery is a preferable and tolerable method in the treatment of malignant pleural mesothelioma. While evaluating surgical indications, it should be kept in mind that cases with epithelial mesothelioma may benefit more from surgical treatment.en_US
dc.identifier.doi10.5606/tgkdc.dergisi.2023.24329
dc.identifier.endpage387en_US
dc.identifier.issn1301-5680
dc.identifier.issue3en_US
dc.identifier.pmid37664769en_US
dc.identifier.scopus2-s2.0-85168625388en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage381en_US
dc.identifier.urihttps://doi.org/10.5606/tgkdc.dergisi.2023.24329
dc.identifier.urihttps://hdl.handle.net/11454/101444
dc.identifier.volume31en_US
dc.identifier.wosWOS:001044019100011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBaycinar Medical Publ-Baycinar Tibbi Yayinciliken_US
dc.relation.ispartofTurk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectChemotherapyen_US
dc.subjectchesten_US
dc.subjectmesotheliomaen_US
dc.subjectpleural diseaseen_US
dc.subjectsurvivalen_US
dc.subjectMalignant Pleural Mesotheliomaen_US
dc.subjectIntrathoracic Chemotherapyen_US
dc.subjectChemoperfusionen_US
dc.subjectManagementen_US
dc.subjectCisplatinen_US
dc.subjectSurgeryen_US
dc.titleSurvival of pleurectomy-decortication and hyperthermic chemotherapy in mesotheliomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu